Osteopore International, a Singaporean bone regeneration technology provider 
has debuted on the Australian Securities Exchange with an AUS$5.25million IPO. 
With a strong demand, Osteopore shares opened at 63 cents and rose to as high 
as 80 cents on its first day on the bourse.

Photo - https://photos.prnasia.com/prnh/20190927/2594385-1 
(From Left-Dato Seri Marcus Liew (Asia Cornerstone Asset Management Co), 
Professor Teoh Swee Hin (Chairman of Board of Directors of Osteopore), Stuart 
Carmichael (Director of Ventnor Capital), Dato Ken Low (Asia Cornerstone Asset 
Management Co))

"We are extremely pleased by the support for the company from Australian and 
international investors, and the success of Osteopore's IPO raising shows the 
strong appetite from ASX investors for well-priced technology investment 
opportunities," said Geoff Pocock, executive director of Osteopore. 

Established in 2003, Osteopore utilises its proprietary 3D printing process to 
manufacture customisable bioresorbable 3D scaffolds with biomimetic 
microstructure to create a cell-friendly environment that facilitates natural 
bone regeneration. After the bone is healed, the 3D structure dissolves into 
carbon dioxide and water.

This technology has proven to surpass the limits of bone grafting and has been 
used in more than 20,000 surgeries, with no post-surgery complication rates 
traditionally associated with long term permanent bone implants.

For example, in 2017, an Australian man had to remove his tibia after 
developing a severe infection. Bone grafting had been one solution to help the 
man recover, however this procedure was limited to only a short segment of the 
bone. The ARC Industrial Transformation Training Centre in Additive 
Biomanufacturing then designed a replacement for the man's tibia, which was 
turned into a 3D-printed regenerative implant by Osteopore. The man then 
successfully received the implant surgery.

With the FDA's approval alongside Europe's CE Marking, Osteopore is ahead of 
most small cap biotech and medtech companies on the ASX, many of whom are 
either still in clinical trials or attempting to have their products approved 
by regulatory bodies.

Osteopore banked nearly $1 million in revenue in the 2018 calendar year, which 
was primarily generated in Asian markets including Singapore, Korea and 
Vietnam. The funds raised from the ASX IPO are used to further promote 
Osteoplug, Osteomesh and Osteostrip products in established and emerging 
international markets, while developing new growth opportunities leveraging its 
expertise in regenerative medicine and medical polymers.

"We are excited by the possibilities for improving health outcomes for patients 
as the Osteopore technology is increasingly used by surgeons globally. The 
funds from the IPO will greatly accelerate our sales and marketing efforts and 
enable the company to increasingly supply products to key global markets," said 
Brett Sandercock, non-executive chairman of Osteopore.

SOURCE Osteopore International

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=346392

   Caption: From Left-Dato Seri Marcus Liew (Asia Cornerstone Asset Management 
Co), Professor Teoh Swee Hin (Chairman of Board of Directors of Osteopore), 
Stuart Carmichael (Director of Ventnor Capital), Dato Ken Low (Asia Cornerstone 
Asset Management Co)